Multivariable Cox regression analysis for EFS
| Variable . | HR ± SE . | 95% CI . | P . |
|---|---|---|---|
| Lenalidomide treatment | 0.96 ± 0.09 | 0.79-1.17 | .70 |
| Age | 1.00 ± 0.00 | 1.00-1.01 | .30 |
| WBC | 1.07 ± 0.04 | 1.01-1.15 | .03 |
| 2017 ELN risk group | <.001 | ||
| Favorable | 0.55 ± 0.07 | 0.42-0.71 | <.001 |
| Adverse | 1.48 ± 0.17 | 1.18-1.87 | <.001 |
| Unknown | 0.57 ± 0.21 | 0.27-1.16 | .10 |
| AML type | .04 | ||
| sAML | 1.61 ± 0.30 | 1.11-2.33 | .01 |
| tAML | 1.09 ± 0.28 | 0.66-1.82 | .73 |
| Variable . | HR ± SE . | 95% CI . | P . |
|---|---|---|---|
| Lenalidomide treatment | 0.96 ± 0.09 | 0.79-1.17 | .70 |
| Age | 1.00 ± 0.00 | 1.00-1.01 | .30 |
| WBC | 1.07 ± 0.04 | 1.01-1.15 | .03 |
| 2017 ELN risk group | <.001 | ||
| Favorable | 0.55 ± 0.07 | 0.42-0.71 | <.001 |
| Adverse | 1.48 ± 0.17 | 1.18-1.87 | <.001 |
| Unknown | 0.57 ± 0.21 | 0.27-1.16 | .10 |
| AML type | .04 | ||
| sAML | 1.61 ± 0.30 | 1.11-2.33 | .01 |
| tAML | 1.09 ± 0.28 | 0.66-1.82 | .73 |
The following covariates were considered for this analysis: patient age, WBC × 109/L at diagnosis (log transformation), 2017 ELN risk category1 (values expressed relative to intermediate-risk group), sAML and tAML (relative to de novo AML).